Navigation Links
XTL Biopharmaceuticals Provides Update on Potential Strategic Alternatives
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential assets or to identify a company to merge into or with XTL.

The Company is currently evaluating several merger proposals that have been presented to it by both US and foreign-based companies who operate in and outside of the healthcare space. These discussions are preliminary in nature, and consequently, the timing of and ability to consummate such a transaction cannot be predicted at this time, and the Company may still decide that the distribution of its remaining assets to the shareholders in a liquidation offers the best possible alternative to the shareholders.

XTL has retained an investment banking firm to advise the Company in assessing these potential merger opportunities.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future business prospects, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In particular, we may not be able to consummate a merger transaction with any of the potential merger partners due to certain conditions that are likely to be required by our potential merger partners and regulatory authorities. In addition, our remaining cash resources are scarce and we may be delisted from NASDAQ, both of which may further limit our ability to remain an attractive merger candidate. Any forward-looking statements set forth in this press release speak only as of the date of this press r
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
2. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
3. XTL Biopharmaceuticals Implements Restructuring Plan
4. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
5. Morria Biopharmaceuticals Plc Announces Positive Clinical Results for MRX-4 in its Phase II Clinical Study in Allergic Rhinitis Patients
6. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
7. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
8. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
9. Nomad Bioscience: New Plant Biotechnology Company Founded to Focus on Biomaterials and Biopharmaceuticals
10. Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants
11. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
(Date:8/19/2014)... 19, 2014 Robin Williams’ passing is ... take on an individual. Symptoms range from slowness ... problems swallowing and severe depression. Parkinson’s disease progressively ... of dopamine producing neurons of the brain. As ... that slowly and progressively gets worse, they look for ...
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ... Oral Amphotericin B (Oral Amp B) drug candidate ... ImmuneCarta®, the immune monitoring business unit of Caprion, ... Amp B in reactivating latent HIV viral reservoirs ... with antiretroviral therapy. Memory cells, ...
Breaking Biology Technology:Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3
... ST. LOUIS, Aug. 18 Sigma-Aldrich® Corporation (Nasdaq: ... Borg has been named Vice President and Chief Information ... Borg will lead the Company,s global information systems function ... Chief Financial Officer and Chief Administrative Officer. ...
... Bulletin Board: WDSTD ), a development stage ... initial $3.25 million funding in conjunction with its acquisition ... by Lonza Walkersville ("Lonza Agreement").  Lonza Walkersville is a ... the world,s leading suppliers to the pharmaceutical, healthcare and ...
... in... -- JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010, ... ... ... Results are keyed by longUrl, so we need to grab the first one. for (var r ...
Cached Biology Technology:Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO) 2Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 3Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 4Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 5Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 6Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 7
(Date:8/19/2014)... team of UTSA researchers has been awarded a nearly ... and Training (NCPTT), an office of the National Park ... grant will fund a one-year study of the energy ... historic homes in hot, humid climates. , Radiant barriers ... attics that reflect heat back, thereby reducing the amount ...
(Date:8/19/2014)... Plants are superior to humans and animals in a ... regenerate, which enables them to regrow entire organs. After ... grow back its entire crown. But there is one ... quite literally rooted to the habitats in which they ... elements. In response to this dilemma, plants have developed ...
(Date:8/19/2014)... This news release is available in French . ... Stand: balancing the BENEFITS and RISKS of physical activity ... a stand on the promotion of childhood physical activity ... Applied Physiology, Nutrition, and Metabolism ( APNM ... of knowledge in the area of risk of physical ...
Breaking Biology News(10 mins):UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 2UTSA researcher awarded $38K+ to evaluate energy efficiency options for historic homes 3How steroid hormones enable plants to grow 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 2Taking a stand: Balancing the BENEFITS and RISKS of physical activity in children 3
... model for human exercise? According an article published in the ... habits make it a prime model of cardiovascular fitness. The ... requirements, and, according to the authors, this cold-blooded snake may ... adapting to prolonged exercise and in response to some diseases. ...
... isolated the first human embryonic stem cell lines specifically tailored ... females of various ages, suffering from disease or spinal cord ... Science, which is published by AAAS, the non-profit science society, ... These cell lines will enable the study of human disease ...
... issue of Science holds mixed blessings for scientists who ... The study, conducted by scientists from Cincinnati Children's Hospital ... in Germany, reveals important evidence that tells us more ... other hand, scientists offer caution in regards to the ...
Cached Biology News:Scientists generate patient-specific stem cells, Science study says 2Scientists generate patient-specific stem cells, Science study says 3Scientists generate patient-specific stem cells, Science study says 4Science study holds implications for gene therapy and stem cell biology 2Science study holds implications for gene therapy and stem cell biology 3
...
...
Anti 4-hydroxy-2-hexenal (4-HHE) Monoclonal Antibody (HNEJ-2)...
... in immunostaining ,This solution has effect on ... get clearer signal than the one obtained ... amount of secondary antibody used and exposure ... can have images with high S/N ratio ...
Biology Products: